Hematology

The role of the pharmacist in sickle cell disease management revolves around appropriate pain management.

The drug is being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant.

Cole McCoy, PharmD, and James McCloskey, MD, explain common treatment goals, cytogenetic tests, and considerations that factor into choosing individualized treatment for patients with AML.

James McCloskey, MD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP give a brief synopsis of AML, including its definition, the different types of the condition, and a typical patient’s journey.

Results from a phase 3b study showed that venetoclax combined with azacitidine or decitabine can safely be initiated in a US community-based outpatient setting.

Ginna Laport, MD, discussed the growing body of research surrounding venetoclax.

Efanesoctocog alfa is a novel and investigational recombinant factor VIII therapy that is designed to extend protection from bleeding with a once-weekly prophylactic dosing.

AstraZeneca trial results shows 90% of patients with chronic lymphocytic leukemia surviving for 5 years.

Overall outcomes were consistent with axicabtagene ciloleucel in the real-world setting, regardless of race or ethnicity, in adults with relapsed or refractory large B-cell lymphoma.

Brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine shows improved overall survival compared with standard chemotherapy in patients with previously untreated, advanced stage classical Hodgkin lymphoma.

The FDA approved decitabine/cedazuridine in 2020 for treatment of adults with myelodysplastic syndromes.

The safety profile of valoctocogene roxaparvovec in the phase 1/2 study was consistent with previously reported data, with no delayed-onset treatment-related adverse events (AEs).

Tisagenlecleucel was shown to be effective in high-risk patients, including those who were heavily pretreated or had refractory disease.

The approval is supported by data from a global phase 3 trial assessing the use of the drug for individuals with previously untreated IDH1-mutated acute myeloid leukemia.

Aklilu Tedla, vice president of strategy and business development at Cardinal Health, discusses the cell and gene therapies in the pipeline for approval by the FDA.

After 14 months without ART, a patient with HIV only had transient detection of trace levels of HIV DNA in her blood cells after a stem cell transplant for acute myeloid leukemia.

An international phase 1/2 clinical trial is ongoing for the treatment for individuals with relapsed or refectory acute myeloid leukemia with FLT3 mutation.

Obinutuzumab is a CD20-directed cytolytic antibody used to treat certain types of blood cancer.

Omidubicel is a first-in-class, advanced nicotinamide-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for individuals with blood cancers in need of a transplant.

The advanced cell therapy is under development as an allogeneic hematopoietic stem cell transplant for patients with hematologic malignancies.

Voxelotor (Oxbryta) is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.

Scemblix is indicated for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors.

DuoBody, for treatment of relapsed/refractory large B-cell lymphoma, demonstrates an overall response rate of 63.1%.

Investigational CAR T-cell therapy is currently being evaluated in an ongoing dose escalation phase 1 trial to analyze its safety and tolerability in treating non-Hodgkin lymphoma.

Drs Haumschild, Gilreath and Howe discuss the use of quality initiatives to support pharmacy accreditation through organizations such as URAC.